Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy

Stopped The funding sponsor, EISAI, sold the US rights to the medication and can no longer provide it to patients for the study.

Conditions

• Intractable Epilepsy
• Malignant Glioma
• Seizure Disorder
• WHO Grade 2 Glioma
• WHO Grade 3 Glioma

Interventions

• DRUG: Anticonvulsant Agent
• DRUG: Perampanel
• OTHER: Quality-of-Life Assessment
• OTHER: Questionnaire Administration

Sponsor

Mayo Clinic